These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics. Yamamoto S, Takemori E, Hasegawa Y, Kuroda K, Nakao K, Inukai T, Sakonjyo H, Nishimura T, Nishimori T. Arzneimittelforschung; 1991 Sep; 41(9):913-23. PubMed ID: 1796919 [Abstract] [Full Text] [Related]
3. Antihypertensive action of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride in hypertensive rat models. Tanaka M, Yamamoto S, Nakao K, Inukai T, Ogawa N, Katsumura H, Ohara N, Shukunobe K, Ono H. Arzneimittelforschung; 1991 Jun; 41(6):608-12. PubMed ID: 1930348 [Abstract] [Full Text] [Related]
4. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system. Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T. Arzneimittelforschung; 1985 Jun; 35(7A):1157-62. PubMed ID: 4074429 [Abstract] [Full Text] [Related]
5. Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats. Takemori E, Hasegawa Y, Katahira J, Nakao K, Inukai T. Arzneimittelforschung; 1991 Jun; 41(6):612-5. PubMed ID: 1834066 [Abstract] [Full Text] [Related]
6. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system. Kaneko T, Kitahara A, Ozaki S, Takizawa K, Yamatsu K. Arzneimittelforschung; 1981 Jun; 31(8):1206-12. PubMed ID: 6117290 [Abstract] [Full Text] [Related]
7. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system. Murata T, Sakaya S, Hoshino T, Umetsu T, Hirano T, Nishio S. Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742 [Abstract] [Full Text] [Related]
8. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Liu XP, Pang YJ, Zhu WW, Zhao TT, Zheng M, Wang YB, Sun ZJ, Sun SJ. Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797 [Abstract] [Full Text] [Related]
9. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions. Matsuno Y, Hori H, Oka M, Nakamura H, Ito T, Kadokawa T. Arzneimittelforschung; 1986 Mar; 36(1):62-8. PubMed ID: 3513778 [Abstract] [Full Text] [Related]
10. General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st communication: effects on the central nervous system. Saito T, Fukuda T, Sukamoto T, Yoshidomi M, Morimoto Y, Shimohara K, Ito K. Arzneimittelforschung; 1988 Jan; 38(1):66-9. PubMed ID: 2896509 [Abstract] [Full Text] [Related]
11. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions. Kurumiya S, Miura Y, Nakatsuji K, Dodo M, Hori M, Ito T. Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465 [Abstract] [Full Text] [Related]
12. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions. Teschendorf HJ, Kretzschmar R, Kreiskott H, Weifenbach H. Arzneimittelforschung; 1981 Feb; 31(9a):1580-8. PubMed ID: 7197973 [Abstract] [Full Text] [Related]
13. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems. Hirohashi M, Takasuna K, Kasai Y, Usui C, Kojima H. Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569 [Abstract] [Full Text] [Related]
14. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system. Hirotsu I, Kihara T, Nakamura S, Hattori Y, Hatta M, Kitakaze Y, Takahama K, Hashimoto Y, Miyata T, Ishihara T. Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380 [Abstract] [Full Text] [Related]
15. [Effects of suloctidil on the central and peripheral nervous systems]. Nishi H, Watanabe T, Mori M. Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248 [Abstract] [Full Text] [Related]
17. General pharmacology of recombinant human basic fibroblast growth factor. Okumura M, Yajima M, Nishimura T, Ikeda H, Nishimori T. Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346 [Abstract] [Full Text] [Related]
18. General pharmacology of the non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline. Shirota M, Hayashi M, Kajiwara Y, Kitabatake K, Uruno T, Kubota K. Arzneimittelforschung; 1993 Nov; 43(11):1169-74. PubMed ID: 8292059 [Abstract] [Full Text] [Related]
19. Antihypertensive mechanism of action of the novel angiotensin converting enzyme inhibitor benazepril. Effect on isolated vascular preparations. Kuroda K, Fukuda Y, Nakao K, Inukai T. Arzneimittelforschung; 1990 Sep; 40(9):968-73. PubMed ID: 2080946 [Abstract] [Full Text] [Related]
20. General pharmacology of the new antimuscarinic compound vamicamide. Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K. Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084 [Abstract] [Full Text] [Related] Page: [Next] [New Search]